For research use only. Not for therapeutic Use.
Pomalidomide-PEG1-C2-N3（Cat No.:I018715）is a conjugate of pomalidomide, a potent immunomodulatory drug, with polyethylene glycol (PEG) and a linker group (C2-N3). Pomalidomide itself is used primarily in the treatment of multiple myeloma and other hematologic cancers due to its ability to modulate the immune system, enhance T-cell response, and inhibit angiogenesis. The PEG1 linker increases solubility and stability, while the C2-N3 group likely facilitates targeted delivery of the drug. This conjugate is being explored for potential use in enhancing the efficacy and minimizing side effects of pomalidomide in cancer therapies, though more research is needed.
| CAS Number | 2271036-44-1 |
| Molecular Formula | C₁₇H₁₈N₆O₅ |
| Purity | ≥95% |
| Target | E3 Ligase Ligand-Linker Conjugates |
| IUPAC Name | 4-[2-(2-azidoethoxy)ethylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| InChI | InChI=1S/C17H18N6O5/c18-22-20-7-9-28-8-6-19-11-3-1-2-10-14(11)17(27)23(16(10)26)12-4-5-13(24)21-15(12)25/h1-3,12,19H,4-9H2,(H,21,24,25) |
| InChIKey | NJPMWHWTBBYBDY-UHFFFAOYSA-N |
| SMILES | C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCOCCN=[N+]=[N-] |
| Reference | [1]. Su S, et al. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 2. |
